Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

被引：9

作者：

Kahraman, Seda ^{[1
]}

Erul, Enes ^{[2
]}

Seyyar, Mustafa ^{[3
]}

Gumusay, Ozge ^{[4
]}

Bayram, Ertugrul ^{[5
]}

Demirel, Burcin Cakan ^{[6
]}

Acar, Omer ^{[7
]}

Aksoy, Sercan ^{[2
]}

Baytemur, Naziyet Kose ^{[8
]}

Sahin, Elif ^{[3
]}

Cabuk, Devrim ^{[3
]}

Basaran, Gul ^{[4
]}

Paydas, Semra ^{[5
]}

Yaren, Arzu ^{[6
]}

Guven, Deniz Can ^{[2
]}

Erdogan, Atike Pinar ^{[7
]}

Demirci, Umut ^{[8
]}

Yasar, Alper ^{[9
]}

Bayoglu, Ibrahim Vedat ^{[9
]}

Hizal, Mutlu ^{[1
]}

Gulbagci, Burcu ^{[10
]}

Paksoy, Nail ^{[11
]}

Davarci, Sena Ece ^{[12
]}

Yilmaz, Funda ^{[13
]}

Dogan, Ozlem ^{[14
]}

Orhan, Sibel Oyucu ^{[15
]}

Kayikcioglu, Erkan ^{[16
]}

Aytac, Ali ^{[17
]}

Keskinkilic, Merve ^{[18
]}

Mocan, Eda Eylemer ^{[19
]}

Unal, Olcun Umit ^{[20
]}

Aydin, Esra ^{[21
]}

Yucel, Hakan ^{[22
]}

Isik, Deniz ^{[23
]}

Eren, Onder ^{[24
]}

Uluc, Basak Oyan ^{[4
]}

Ozcelik, Melike ^{[25
]}

Hacibekiroglu, Ilhan ^{[10
]}

Aydiner, Adnan ^{[11
]}

Demir, Hacer ^{[12
]}

Oksuzoglu, Berna ^{[13
]}

Cilbir, Ebru ^{[14
]}

Cubukcu, Erdem ^{[15
]}

Cetin, Bulent ^{[16
]}

Oktay, Esin ^{[17
]}

Erol, Cihan ^{[1
]}

Okutur, Sadi Kerem ^{[26
]}

Yildirim, Nilgun ^{[27
]}

Alkan, Ali ^{[28
]}

Selcukbiricik, Fatih ^{[29
]}

机构：

[1] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Dept Med Oncol, TR-06800 Ankara, Turkiye

[2] Hacettepe Univ, Canc Inst, Dept Med Oncol, TR-06590 Ankara, Turkiye

[3] Kocaeli Univ, Med Fac Hosp, Dept Med Oncol, TR-41000 Kocaeli, Turkiye

[4] Acibadem Univ, Sch Med, Dept Med Oncol, TR-34750 Istanbul, Turkiye

[5] Cukurova Univ, Dept Med Oncol, TR-01330 Adana, Turkiye

[6] Pamukkale Univ Hosp, Dept Med Oncol, TR-20160 Denizli, Turkiye

[7] Manisa Celal Bayar Univ Hosp, Dept Med Oncol, TR-45120 Mersin, Turkiye

[8] Ankara Mem Hosp, Dept Med Oncol, TR-06520 Ankara, Turkiye

[9] Marmara Univ, Dept Med Oncol, Pendik Res & Applicat Hosp, TR-34899 Istanbul, Turkiye

[10] Sakarya Univ, Sch Med, Dept Med Oncol, TR-54187 Sakarya, Turkiye

[11] Istanbul Univ, Dept Med Oncol, TR-34093 Istanbul, Turkiye

[12] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, TR-03200 Afyonkarahisar, Turkiye

[13] Dr Abdurrahman Yurtaslan Ankara Oncol Training & R, Dept Med Oncol, TR-06200 Ankara, Turkiye

[14] Ankara Etlik City Hosp, Dept Med Oncol, TR-06170 Ankara, Turkiye

[15] Uludag Univ, Dept Med Oncol, TR-16059 Bursa, Turkiye

[16] Suleyman Demirel Univ, Dept Med Oncol, TR-32260 Isparta, Turkiye

[17] Aydin Adnan Menderes Univ, Dept Med Oncol, Training & Res Hosp, TR-09100 Aydin, Turkiye

[18] Dokuz Eylul Univ, Res & Applicat Hosp, Dept Med Oncol, TR-35340 Izmir, Turkiye

[19] Ankara Univ, Dept Med Oncol, TR-06080 Ankara, Turkiye

[20] Tepecik Training & Res Hosp, Dept Med Oncol, TR-35180 Izmir, Turkiye

[21] Recep Tayyip Erdogan Univ Training & Res Hosp, Dept Med Oncol, TR-53020 Rize, Turkiye

[22] Gaziantep Univ, Dept Med Oncol, TR-27580 Gaziantep, Turkiye

[23] Kocaeli Med Pk Hosp, Dept Med Oncol, TR-41140 Kocaeli, Turkiye

[24] Selcuk Univ, Dept Med Oncol, Med Fac Hosp, TR-42250 Konya, Turkiye

[25] Umraniye Training & Res Hosp, Dept Med Oncol, TR-34764 Istanbul, Turkiye

[26] Istanbul Arel Univ, Bahcelievler Mem Hosp, Dept Med Oncol, TR-34537 Istanbul, Turkiye

[27] Firat Univ Hosp, Dept Med Oncol, TR-23200 Elazig, Turkiye

[28] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Med Oncol, TR-48000 Mugla, Turkiye

[29] Koc Univ Hosp, Dept Med Oncol, TR-34010 Istanbul, Turkiye

[30] Elazig Fethi Sekin City Hosp, Dept Med Oncol, TR-23280 Elazig, Turkiye

[31] Acibadem Bodrum Hosp, Dept Med Oncol, TR-48420 Mugla, Turkiye

[32] Canakkale Onsekiz Mart Univ, Dept Med Oncol, Res & Practice Hosp, TR-17100 Canakkale, Turkiye

[33] Adana City Training & Res Hosp, Dept Med Oncol, TR-01230 Adana, Turkiye

[34] Kocaeli Derince Training & Res Hosp, Dept Med Oncol, TR-41310 Kocaeli, Turkiye

[35] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, TR-46050 Kahramanmaras, Turkiye

[36] Necmettin Erbakan Univ, Dept Med Oncol, Meram Med Fac Hosp, TR-42080 Konya, Turkiye

[37] Gulhane Training & Res Hosp, Dept Med Oncol, TR-06010 Ankara, Turkiye

[38] Mersin City Hosp, Dept Med Oncol, TR-96015 Mersin, Turkiye

[39] Namik Kemal Univ, Dept Med Oncol, Hlth Applicat & Res Hosp, TR-59030 Tekirdag, Turkiye

[40] Van Yuzuncu Yil Univ, Dursun Odabas Hosp, Dept Med Oncol, TR-65090 Van, Turkiye

[41] Manisa City Hosp, Dept Med Oncol, TR-45040 Manisa, Turkiye

[42] Konya City Hosp, Dept Med Oncol, TR-42020 Konya, Turkiye

[43] Ordu State Hosp, Dept Med Oncol, TR-52200 Ordu, Turkiye

[44] Aydin Ataturk State Hosp, Dept Med Oncol, TR-09020 Aydin, Turkiye

[45] Izmir Bozyaka Training & Res Hosp, Dept Med Oncol, TR-35170 Izmir, Turkiye

[46] Anadolu Med Ctr, Dept Med Oncol, TR-34758 Istanbul, Turkiye

来源：

FUTURE ONCOLOGY | 2023年

关键词：

CDK; 4; 6; inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole;

D O I：

10.2217/fon-2022-1287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

引用

页码：727 / 736

页数：10

共 50 条

[1] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Lopez-Tarruella, Sara
Jerez, Yolanda
Marquez-Rodas, Ivan
Echavarria, Isabel
Martin, Miguel
FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
[2] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, Aki
Henry, N. Lynn
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
[3] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Bingnan Zhang
Elisa F. Long
Breast Cancer Research and Treatment, 2019, 175 : 775 - 779
[4] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Zhang, Bingnan
Long, Elisa F.
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 775 - 779
[5] Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
Liu, Qi
Hou, Lingli
Zhao, Ying
Yang, Hongwei
Mo, Zhengying
Yu, Fei
CLINICS, 2023, 78
[6] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
Go, Makiko
Kimura, Michio
Yamada, Shiori
Kamei, Keitaro
Noguchi, Yoshinori
Usami, Eiseki
Yoshimura, Tomoaki
ONCOLOGY, 2024,
[7] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Walker, Amanda J.
Wedam, Suparna
Amiri-Kordestani, Laleh
Bloomquist, Erik
Tang, Shengui
Sridhara, Rajeshwari
Chen, Wei
Palmby, Todd R.
Zirkelbach, Jeanne Fourie
Fu, Wentao
Liu, Qi
Tilley, Amy
Kim, Geoffrey
Kluetz, Paul G.
McKee, Amy E.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
[8] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Pernas, Sonia
Sanfeliu, Esther
Villacampa, Guillermo
Salvador, Javier
Perello, Antonia
Gonzalez, Xavier
Jimenez, Begona
Merino, Maria
Palacios, Patricia
Pascual, Tomas
Alba, Emilio
Villanueva, Lorea
Chillara, Samyukta
Ferrero-Cafiero, Juan Manuel
Galvan, Patricia
Prat, Aleix
Ciruelos, Eva
NPJ BREAST CANCER, 2024, 10 (01)
[9] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Shah, Anand
Bloomquist, Erik
Tang, Shenghui
Fu, Wentao
Bi, Youwei
Liu, Qi
Yu, Jingyu
Zhao, Ping
Palmby, Todd R.
Goldberg, Kirsten B.
Chang, C. J. George
Patel, Paresma
Alebachew, Elleni
Tilley, Amy
Pierce, William F.
Ibrahim, Amna
Blumenthal, Gideon M.
Sridhara, Rajeshwari
Beaver, Julia A.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
[10] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
Go, Makiko
Kimura, Michio
Yamada, Shiori
Usami, Eiseki
Noguchi, Yoshihiro
Yoshimura, Tomoaki
JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266

← 1 2 3 4 5 →